Stevanato Group S.p.A. (NYSE:STVN) reported fourth-quarter results on Wednesday that came in ahead of analyst expectations.
Shares of the company surged 16.70% in after-hours trading following the announcement, as investors responded to continued strength in its high-value solutions segment.
The Italian provider of drug containment and delivery systems reported adjusted diluted earnings per share of €0.18 for the fourth quarter, slightly above the analyst consensus estimate of €0.17.
Revenue rose 5% year over year — or 7% at constant exchange rates — to €346.5 million, exceeding the consensus estimate of €333.79 million and increasing from €330.6 million in the same period last year. High-value solutions accounted for 49% of total revenue, reaching a record €171.4 million.
The results were supported by a 10% increase in revenue within the company’s Biopharmaceutical and Diagnostic Solutions division. Gross profit margin expanded by 120 basis points to 30.9%, while adjusted EBITDA margin improved by 70 basis points to 28.2%.
Franco Stevanato, Chief Executive Officer, commented, “We concluded fiscal year 2025 with another solid quarter that led to positive full-year performance underpinned by strong top-line growth, a favorable mix of high value solutions, and expanded margins.”
For fiscal 2026, Stevanato expects adjusted diluted earnings per share to range between €0.59 and €0.63, with a midpoint of €0.61, slightly below the analyst consensus forecast of €0.64.
The company anticipates revenue of between €1.26 billion and €1.29 billion, implying a midpoint of €1.275 billion, broadly aligned with the consensus estimate of €1.28 billion. Adjusted EBITDA is projected in a range of €331.8 million to €346.9 million.
Stevanato also noted that GLP-1 treatments accounted for roughly 19% to 20% of total revenue in 2025, highlighting the company’s growing presence in the expanding biologics market.